IGC Pharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
IGC$0.20+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| September 30,2026 (Unaudited)($) | December 31,2025(Audited)($) | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 377 | 900 |
| Accounts receivable, net | 68 | 12 |
| Inventory | 643 | 640 |
| Current investment | 36 | 38 |
| Deposits and advances | 182 | 200 |
| Total current assets | 1,306 | 1,790 |
| Non-current assets: | ||
| Intangible assets, net | 5,740 | 5,101 |
| Property, plant, and equipment, net | 2,031 | 2,141 |
| Claims and advances | 652 | 669 |
| Operating lease asset | - | 11 |
| Total non-current assets | 8,423 | 7,922 |
| Total assets | 9,729 | 9,712 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | 1,661 | 1,014 |
| Accrued liabilities and others | 698 | 962 |
| Current loans | 741 | 180 |
| Total current liabilities | 3,100 | 2,156 |
| Non-current liabilities: | ||
| Non-current loans | 128 | 131 |
| Operating lease liability | - | 2 |
| Total non-current liabilities | 128 | 133 |
| Total liabilities | 3,228 | 2,289 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of September 30, 2026, and December 31, 2025. | ||
| Common stock and additional paid-in capital, $0.0001 par value: 600,000,000 shares authorized; 114,350,306 and 95,038,026 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively. | 144,487 | 138,014 |
| Accumulated other comprehensive loss | (5,712) | (5,701) |
| Accumulated deficit | (132,274) | (124,890) |
| Total stockholders’ equity | 6,501 | 7,423 |
| Total liabilities and stockholders’ equity | 9,729 | 9,712 |
| September 30, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.